AXA1957

DIETARY_SUPPLEMENT2 trials

Sponsors

Axcella Health, Inc

Conditions

NAFLD

Unknown Phase

Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

CompletedNCT04073368

Axcella Health, IncNAFLD

Start: 2018-12-03End: 2020-09-03Updated: 2021-07-06

Study of the Safety and Tolerability of AXA1957 in Adolescent Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

TerminatedNCT04073407

Axcella Health, IncNAFLD

Start: 2019-07-27End: 2020-09-01Updated: 2021-09-23

Related Papers

752-P: LIVRQNac (AXA1125) Enhances Insulin Sensitivity in Primary Human Hepatocytes and in Subjects with NAFLD and T2D

Diabetes2021-06-01